SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

VCX is trending as investors react to its recent NYSE debut and the significant premium currently trading above its net asset value. The community is actively debating the impact of a six-month share lockup on the float, with many speculating on the fund's potential for future volatility driven by its exposure to high-profile private AI companies like Anthropic, SpaceX, and OpenAI.

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

The SPERMWHALE meme coin is driving intense community debate over whether it represents a high-potential speculative play or a classic pump-and-dump scheme. Traders are actively comparing its viral potential to other successful meme tokens while others remain highly skeptical of its lack of intrinsic utility.

Fastly, Inc. provides real-time content delivery network services. It offers edge compute, edge delivery, edge security, edge applications like load balancing and image optimization, video on demand, and managed edge delivery. The company was founded by Artur Bergman, Tyler McMullen, Simon Wistow, and Gil Penchina in March 2011 and is headquartered in San Francisco, CA.

Fastly Inc - Ordinary Shares - Class A

Fastly Inc

Fastly Inc. is experiencing intense volatility and community debate as traders grapple with a sharp post-earnings rally, heavy insider selling, and high short interest. While bulls highlight potential for long-term growth driven by AI and edge computing, bears argue the valuation is detached from fundamentals, leading to frequent clashes over technical resistance levels and short-squeeze potential.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings is experiencing heightened volatility and selling pressure following a post-earnings sell-off, leading the community to intensely debate whether the decline is driven by technical gap-filling, broader market weakness, or concerns regarding management's long-term strategy and PepsiCo's influence. Investors are actively discussing the stock's valuation and the potential for a recovery, with many closely monitoring technical support levels while expressing frustration over the discrepancy between strong financial performance and the recent price action.

Merlin, Inc. is an aerospace and defense technology company focused on developing autonomous flight solutions. The company is building an operating system of record for autonomous aviation, with its Merlin Pilot system enabling a wide range of aircraft and mission profiles. Its technology has been validated through hundreds of autonomous flights conducted at test facilities worldwide. The company is headquartered in Boston, MA.

Merlin Inc.

Marlin Business Services Corp.

Marlin Business Services is currently facing significant community debate and uncertainty as investors weigh reports of potential acquisitions against ongoing legal investigations and insider trading activity. The conversation remains highly fragmented, with participants questioning the stock's future direction while closely monitoring SEC filings for signs of corporate restructuring or leadership changes.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is seeing increased volatility as investors weigh the stock's role as a defensive holding against regulatory risks and uncertainties surrounding upcoming Medicare Advantage rate announcements. While the community remains divided between those capitalizing on short-term technical swings and those banking on a long-term recovery driven by the stock's fundamental scale and dividend stability, recent sentiment is being heavily influenced by broader institutional rebalancing and sector-wide regulatory scrutiny.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is experiencing significant volatility as the community debates the veracity of recent claims regarding ceasefire negotiations with Iran. Market participants remain sharply divided, with bulls pointing to potential market-moving diplomatic breakthroughs, while skeptics view the fluctuations as a politically motivated attempt to manipulate market sentiment.

The Estée Lauder Companies, Inc. engages in the manufacture of skin care, makeup, fragrance and hair care products. It sells products under Estée Lauder, Clinique, Origins, MAC, Bobbi Brown, La Mer, Jo Malone London, Aveda and Too Faced. The company was founded by Estee Lauder and Joseph Lauder in 1946 and is headquartered in New York, NY.

Estee Lauder Cos., Inc. - Ordinary Shares - Class A

Estee Lauder Cos. Inc

Estee Lauder is in the spotlight as investors debate the impact of potential merger talks with Spanish beauty group Puig, a move that community members view as a strategic play to achieve global scale amid the company's broader turnaround efforts. While some discuss the long-term potential of this consolidation, others are closely tracking how tariff-related headwinds and integration risks could influence share price volatility.

$4CHAN is a meme token on the Ethereum Network.   4ChanToken represents a global crypto community that pays homage to the memetic powerhouses of the internet as Pepe, Doge, Shib and all major memes inventor combining them all into one super meme token that is $4CHAN. At its core, 4ChanToken embodies the untamed spirit of the notorious 4chan imageboard, where iconic memes are born, nurtured, and unleashed upon the world. With an unyielding spirit of irreverence and a touch of mischief, $4CHAN has emerged as the darling of meme enthusiasts, internet dwellers, and crypto aficionados alike.   The foundation of 4ChanToken lies in its community. We’ve harnessed the chaotic energy of this digital realm to create a currency that celebrates the power of memetic expression, empowering users to engage in a truly unique and decentralized economy. As a passionate supporter, you’ll join a vibrant ecosystem where dank memes and viral sensations are the lifeblood of commerce. 4ChanToken is more than just a digital currency – it’s the place where memes are born.  The ultimate playground for memelords and crypto degens. Based on the simplicity of holdrs/volume operating a store of value.  The identification of this value is best described as 'digital gold'. That $4chan can ultimately represent a superior store of value relative to all other forms of memecoins by embodying all memes in one token as the factual birthplace of all popular memes.

4Chan

4CHAN is trending as the community positions the token as the 'bitcoin of memecoins,' emphasizing its origins and the 'meme magick' driving its decentralized, exchange-free ecosystem. Investors are actively discussing the potential of its high supply of zeros, framing the current market fluctuations as a strategic buying opportunity for long-term holders aiming for generational gains.

FUST (Fusion token) is the companion token of FUSD - with tokenomics which mirror those of a typical cryptocurrency. FUST can be placed in the FUST Fusion Miner and used to mine free FUSD. FUST has tokenomics which mirror those of a typical cryptocurrency, and allows those Degens who buy into the FUSD philosophy - but who also enjoy the thrill of chasing fast green candles - to make their play within the structure of the FUSD ecosystem and benefit from the best of both worlds; the possibility of a fast ride upwards whilst earning a passive income paid in our appreciating stable token courtesy of their FUST bag.

FUST Token

The FUST ecosystem is gaining momentum as investors highlight its unique model of generating passive income through the appreciating FUSD stablecoin. Community sentiment remains bullish, with many focusing on the ongoing distribution rewards and the project's strategy to provide yield-bearing utility in the stablecoin space.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The acquisition is expected to boost Servier’s position in pediatric low-grade glioma treatments.</li><li>This acquisition aligns with Servier’s long-term strategy to develop innovative oncology treatments by 2030.</li><li>In February, Day One reported strong momentum for its lead therapy, OJEMDA.</li></ul>Day One Biopharmaceuticals, Inc. (DAWN) announced on Friday that it has entered into an acquisition agreement with Servier, an independent pharmaceutical company managed by a foundation.The deal, valued at roughly $2.5 billion, will see Servier purchase Day One shares for $21.50 each in cash, marking a 64% premium over DAWN’s closing price on Thursday.<h2 class="st-heading-2">Expansion In Oncology</h2>The acquisition is expected to boost Servier’s position in pediatric low-grade glioma treatments and broaden its cancer pipeline for both adults and children facing high unmet medical needs.Following the announcement,&nbsp;<a href="https://stocktwits.com/symbol/DAWN">Day One Biopharmaceuticals stock</a> surged over 65% on Friday’s premarket.&nbsp;On Stocktwits, retail sentiment around the stock remained in ‘extremely bullish’ territory amid ‘extremely high’ message volume levels.<h2 class="st-heading-2">Pipeline Growth And 2030 Ambition</h2>This acquisition aligns with Servier’s long-term strategy to develop innovative oncology treatments by 2030. The addition of Day One’s programs, ranging from early-stage research to phase 3 trials, enhances Servier’s capacity to deliver solutions for cancers with critical unmet needs.<blockquote>“Joining Servier represents a unique opportunity to extend the reach of our science and our lead program in pediatric low‑grade glioma.”-Jeremy Bender, CEO, Day One</blockquote>In February, Day One&nbsp;reported strong momentum for its lead therapy, OJEMDA, highlighting prescription volumes for OJEMDA reached 1,394 in the fourth quarter of 2025, with total prescriptions for the year at 4,635, marking a 181% year-on-year (YOY) growth.&nbsp;The company said updated three-year results from the Phase 2 FIREFLY-1 trial demonstrated durable responses and long-term safety of OJEMDA in relapsed or refractory pediatric low-grade glioma (pLGG). Enrollment for the pivotal Phase 3 FIREFLY-2 trial evaluating OJEMDA in frontline pLGG remains on schedule, with full enrollment expected in the first half of 2026.DAWN stock traded over 132% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/aspi-stock-in-spotlight-as-company-strengthens-us-nuclear-fuel-supply-chain-with-new-deal/cZdLbbRRIEr">ASPI Stock In Spotlight As Company Strengthens US Nuclear Fuel Supply Chain With New Deal</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Day One Biopharmaceuticals logo is displayed on the screen of a tablet.

Why Did DAWN Skyrocket Over 65% Pre-Market Today? 

Pharma firm Servier is set to acquire Day One Biopharmaceuticals’ shares for $21.50 each in cash, valuing the deal at $2.5 billion.

Equity

Pharma firm Servier is set to acquire Day One Biopharmaceuticals’ shares for $21.50 each in cash, valuing the deal at $2.5 billion.


<ul class="summary-bullets"><li>The company reported Q4 revenue of $92.02 million with an earnings per share (EPS) of $0.15.</li><li>Since the&nbsp;YUTREPIA launch, the company has received more than 3,600 unique prescriptions.</li><li>The therapy’s adoption rate has remained strong, with the conversion from prescription to patient treatment staying at or above 85%.</li></ul>Liquidia Corp. (LQDA) on Thursday released its financial results for the fourth quarter (Q4), highlighting strong early traction in the commercial rollout of its respiratory drug, YUTREPIA.&nbsp;The company reported Q4 revenue of $92.02 million&nbsp;with an earnings per share (EPS) of $0.15. While revenue surpassed the analysts’ consensus estimate of $83.70 million, EPS came in below the $0.19 estimate, according to Fiscal AI data.&nbsp;<h2 class="st-heading-2">YUTREPIA Launch Drives Commercial Momentum</h2>The North Carolina-based company reported significant prescription growth for YUTREPIA since its U.S. launch in June 2025, with thousands of patients now receiving therapy. The drug’s early performance has become a key contributor to Liquidia’s improving financial outlook and operational momentum.Product revenue from YUTREPIA reached approximately $148.3 million in 2025,&nbsp;including about $90.1 million generated during the fourth quarter alone.<blockquote>“We believe YUTREPIA and L606 have the potential to establish a new standard for the use of inhaled prostacyclin as a critical therapeutic modality across serious and progressive cardiopulmonary diseases.”-Roger Jeffs, CEO, Liquidia&nbsp;</blockquote>Following the update,&nbsp;<a href="https://stocktwits.com/symbol/LQDA">Liquidia’s stock</a> traded over 6% higher in Thursday’s premarket.&nbsp;On Stocktwits, retail sentiment around the stock jumped to ‘bullish’ from ‘bearish’ territory the previous day. Message volume flipped to ‘high’ from ‘normal’ in 24 hours.&nbsp;<h2 class="st-heading-2">What’s Next?&nbsp;</h2>Since the&nbsp;YUTREPIA launch, the company has received more than 3,600 unique prescriptions, with over 2,900 patients already starting treatment. The therapy’s adoption rate has remained strong, with the conversion from prescription to patient treatment staying at or above 85%.Jeffs said the company plans to increase the number of doctors prescribing the treatment, expand the sales team, add more clinical data for YUTREPIA through several new studies, and move L606 into key late-stage trials, all using funds generated from business operations.LQDA stock has gained over 121% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/meta-lacks-deep-pool-of-cloud-demand-unlike-google-and-amazon-says-arete/cZdQYbhRI3T">Meta Lacks The 'Deep Pool' Of Cloud Demand, Unlike Google And Amazon, Says Arete</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Liquidia Corporation logo is seen displayed on a smartphone screen.

Liquidia Stock Gains Premarket On Q4 Revenue Beat – Investors Are Betting On YUTREPIA Growth 

Product revenue from YUTREPIA reached approximately $148.3 million in 2025, including about $90.1 million generated during the fourth quarter alone.

<ul class="summary-bullets"><li>The study enrolled 366 patients, who were randomized to receive either BCG alone or ANKTIVA in combination with BCG.</li><li>Interim analysis of the Phase 2 trial showed 84% of patients on the combo maintained a complete response, compared to 52% on BCG alone at nine months.</li><li>ImmunityBio’s 431% revenue growth in Q4 was largely driven by ANKTIVA sales, the company said.</li></ul>Shares of ImmunityBio (IBRX) reversed pre-market gains to trade 3% lower on Thursday&nbsp;after the company completed enrollment ahead of schedule in its Phase 2 ANKTIVA trial and reported that an FDA-requested interim analysis showed significantly longer complete responses with no major safety concerns.The Phase 2 trial studied ANKTIVA plus Bacillus Calmette-Guérin (BCG) in patients with BCG-naïve non-muscle invasive bladder cancer. The study enrolled 366 patients, who were randomized to receive either BCG alone or ANKTIVA in combination with BCG.The company plans to submit a biologics license application by the fourth quarter of 2026.&nbsp;Last week, the European Commission <a href="https://stocktwits.com/news-articles/markets/equity/immunitybio-inks-partnerships-to-launch-cancer-drug-in-saudi-arabia/cZRNf8cR4xF">granted</a> conditional marketing approval for Anktiva to treat BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ.<h2 class="st-heading-2">ANKTIVA-BCG Combo Significantly Improves Complete Response Duration</h2>An interim analysis requested by the U.S. Food and Drug Administration (FDA) showed that the combination significantly improved the duration of complete response, with no major safety concerns. At nine months, 84% of patients on the combo maintained a complete response, compared with 52% on BCG alone.“We are encouraged by these interim results and await the final unblinding of the completed trial. If approved, ANKTIVA plus BCG could offer a new treatment option earlier in the disease course for patients with NMIBC CIS, building on the therapy’s existing approval in the BCG-unresponsive setting,” said Patrick Soon-Shiong, Chairman and Global Chief Scientific and Medical Officer of ImmunityBio.ANKTIVA continues to power ImmunityBio’s growth, with fourth-quarter net product revenue soaring 431% to $38.3 million, beating Wall Street expectations on strong sales of the drug.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on for <a href="https://stocktwits.com/symbol/IBRX/sentiment">IBRX</a> Stocktwits has remained ‘extremely bullish’ zone for the past six months, while message volumes have been ‘extremely high’.<img src="https://news.stocktwits-cdn.com/IBRX_jpg_b893b9958b.webp" alt="IBRX.jpg">One user said the trial’s outcome is strong enough to justify considering Anktiva + BCG as the “standard of care in BCG-naive NMIBC.”<stembedurl>https://stocktwits.com/Adi121/message/645956934</stembedurl>Another user expects consolidation before the next leg of the rally.<stembedurl>https://stocktwits.com/Texas12/message/645972831</stembedurl>Year-to-date, the stock has shot up 350%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an ImmunityBio company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

IBRX Stock Reverses Pre-Market Gains After ANKTIVA Combo Shows Stronger Bladder Cancer Responses – Retail Sees Consolidation Before Next Leg Up

The company said it plans to submit a biologics license application by the fourth quarter of 2026.

Biotech ETFs Hovering Around a 52-Week: Here's Why 

Biotech is back! Regulatory tailwinds, cheaper valuations, and Fed cut hopes are boosting ETFs like XBI and IBB. Is the rebound just starting?

Biotech ETFs Bounce Back in 2025: Here's Why  

Biotech ETFs rally. IBB, ARKG, SBIO, BBC, CANC and BBP soar as Fed rate cut optimism, FDA approvals, deals and cheaper valuations drive the space in 2025.

BBP
ETFis Series Trust I - Virtus LifeSci Biotech Products ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest BBP News

BBPETFis Series Trust I - Virtus LifeSci Biotech Products ETF